Medtronic (NYSE:MDT) Stock Rating Upgraded by Wall Street Zen

Posted by George Bondi on Nov 10th, 2026

Medtronic (NYSE:MDT – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Sunday, Wall Street Zen reports.

A number of other equities research analysts have also recently commented on MDT. Bank of America lifted their price objective on Medtronic from $95.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, September 2nd. UBS Group reissued a “cautious” rating on shares of Medtronic in a research note on Wednesday, October 14th. Needham & Company LLC restated a “buy” rating on shares of Medtronic in a report on Thursday, September 17th. Weiss Ratings upgraded Medtronic from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, October 19th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $118.00 price target on shares of Medtronic in a research note on Wednesday, September 2nd. Eighteen investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Medtronic has a consensus rating of “Moderate Buy” and a consensus price target of $102.88.

Check Out Our Latest Report on MDT

Medtronic Price Performance

Shares of MDT stock opened at $102.73 on Friday. The stock has a 50-day moving average price of $92.93 and a 200 day moving average price of $88.46. The company has a quick ratio of 1.54, a current ratio of 2.07 and a debt-to-equity ratio of 0.50. The firm has a market cap of $131.41 billion, a price-to-earnings ratio of 18.35, a PEG ratio of 2.46 and a beta of 0.56. Medtronic has a 12 month low of $73.31 and a 12 month high of $106.33.

Medtronic (NYSE:MDT – Get Free Report) last released its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.39 by $0.06. The company had revenue of $9.76 billion for the quarter, compared to the consensus estimate of $9.55 billion. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The company’s revenue was up 13.7% compared to the same quarter last year. During the same period in the prior year, the company posted $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Research analysts expect that Medtronic will post 5.98 EPS for the current year.

Insider Buying and Selling

In other Medtronic news, EVP Michael Marinaro sold 10,420 shares of the business’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $96.00, for a total value of $1,000,320.00. Following the completion of the transaction, the executive vice president directly owned 105,916 shares of the company’s stock, valued at approximately $10,167,936. The trade was a 8.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Geoffrey Martha sold 50,000 shares of the stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $95.00, for a total value of $4,750,000.00. Following the completion of the sale, the chief executive officer owned 277,866 shares of the company’s stock, valued at $26,397,270. This trade represents a 15.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 61,903 shares of company stock valued at $5,889,203. 0.27% of the stock is owned by company insiders.

Hedge Funds Weigh In On Medtronic

Several institutional investors have recently modified their holdings of the business. WCM Investment Management LLC acquired a new stake in Medtronic during the 1st quarter worth approximately $965,922,000. First Eagle Investment Management LLC boosted its holdings in shares of Medtronic by 37.2% in the second quarter. First Eagle Investment Management LLC now owns 13,783,983 shares of the medical technology company’s stock valued at $1,078,321,000 after buying an additional 3,739,288 shares during the period. Cullen Capital Management LLC acquired a new position in shares of Medtronic in the second quarter valued at approximately $202,764,000. State Street Corp boosted its holdings in shares of Medtronic by 2.7% in the second quarter. State Street Corp now owns 63,399,315 shares of the medical technology company’s stock valued at $5,005,320,000 after buying an additional 1,658,301 shares during the period. Finally, Amundi increased its position in shares of Medtronic by 36.3% during the first quarter. Amundi now owns 6,070,236 shares of the medical technology company’s stock worth $525,986,000 after acquiring an additional 1,616,739 shares in the last quarter. Institutional investors own 82.06% of the company’s stock.

Medtronic Company Profile

(Get Free Report)

Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products.

The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.

Medtronic is headquartered in Dublin, Ireland, and maintains significant operations in Minnesota, where the company was founded.